Panobinostat potentiates the cytotoxic effects of ara-C and daunorubicin on acute myeloid leukemia cells through suppressing the DNA damage response

被引：0
|
作者：
Xie, Chengzhi [1 ]
Edwards, Holly [1 ]
Drenberg, Christina [2 ]
Baker, Sharyn D. [2 ]
Inaba, Hiroto [2 ]
Buck, Steven A. [3 ]
Taub, Jeffrey W. [3 ]
Ge, Yubin [1 ]
机构：
[1] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[2] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[3] Childrens Hosp Michigan, Detroit, MI 48201 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-2739
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2739
引用
收藏
页数：2
相关论文
共 50 条
  • [1] LONG-TERM RESULTS IN ACUTE MYELOID-LEUKEMIA TREATED WITH CONVENTIONAL DAUNORUBICIN, ARA-C (DA) AND THIOGUANINE, ARA-C, DAUNORUBICIN (TAD) POLYCHEMOTHERAPY
    FREUND, M
    LINK, H
    BODENSTEIN, H
    POLIWODA, H
    BLUT, 1986, 53 (03): : 241 - 241
  • [2] Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage
    Xie, Chengzhi
    Edwards, Holly
    Caldwell, J. Timothy
    Wang, Guan
    Taub, Jeffrey W.
    Ge, Yubin
    MOLECULAR ONCOLOGY, 2015, 9 (02) : 409 - 421
  • [3] DAE (DAUNORUBICIN, ARA-C, AND ETOPOSIDE) AND INTERMEDIATE DOSE ARA-C FOR REMISSION INDUCTION AND CONSOLIDATION TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    HWANG, WL
    YOUNG, JH
    GAU, JP
    HU, HT
    TSAI, YT
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (06): : 531 - 534
  • [4] Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
    Richard L Momparler
    Experimental Hematology & Oncology, 2 (1)
  • [5] Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
    Momparler, Richard L.
    EXPERIMENTAL HEMATOLGY & ONCOLOGY, 2013, 2
  • [6] VARIATION IN SENSITIVITY OF DNA-SYNTHESIS TO ARA-C IN ACUTE MYELOID-LEUKEMIA
    HARRIS, AL
    GRAHAMESMITH, DG
    BRITISH JOURNAL OF HAEMATOLOGY, 1980, 45 (03) : 371 - 379
  • [7] Topoisomerase IIα expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C
    Tina, Elisabet
    Prenkert, Malin
    Hoglund, Martin
    Paul, Christer
    Tidefelt, Ulf
    ONCOLOGY REPORTS, 2009, 22 (06) : 1527 - 1531
  • [8] SMALL DOSES OF ARA-C IN THE TREATMENT OF ACUTE MYELOID-LEUKEMIA - DIFFERENTIATION OF MYELOID-LEUKEMIA CELLS
    HOUSSET, M
    DANIEL, MT
    DEGOS, L
    BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (01) : 125 - 129
  • [9] THE RELATIONSHIP OF ARA-C METABOLISM INVITRO TO THERAPEUTIC RESPONSE IN ACUTE MYELOID-LEUKEMIA
    HARRIS, AL
    GRAHAMESMITH, DG
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (01) : 30 - 35
  • [10] Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML)
    Erba, H. P.
    Rizzieri, D. A.
    O'Donnell, M. R.
    Lundberg, A. S.
    Ajami, A. M.
    Rampersad, A. D.
    Capizzi, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345